Previous Article | Next Article ![]()
Journal of Clinical Microbiology, October 2004, p. 4686-4696, Vol. 42, No. 10
0095-1137/04/$08.00+0 DOI: 10.1128/JCM.42.10.4686-4696.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Department of Microbiology, Division of Pathology and Laboratory Medicine, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada,1 Laboratoire Mixte Pasteur-Necker de Recherche sur les Streptocoques et Streptococcies and Unité INSERM U570, Faculté de Médecine Necker-Enfants Malades, Paris, France,2 Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia3
Received 3 March 2004/ Returned for modification 2 April 2004/ Accepted 7 June 2004
|
|
|---|
|
|
|---|
S. pneumoniae is a member of the Streptococcus mitis-Streptococcus oralis group (the Smit group) of viridans group streptococci, which includes S. mitis, S. oralis, Streptococcus cristatus, Streptococcus infantis, and Streptococcus peroris. Differentiation of S. pneumoniae from other viridans group streptococci, including members of the Smit group, has conventionally been based on phenotypic characteristics, most commonly by demonstrating optochin (OPT) susceptibility and/or solubility in bile (sodium deoxycholate) (18). Identification by these two tests is satisfactory when isolates from sterile sites are tested (16). However, identification is often problematic when samples from nonsterile sites, such as respiratory samples, are tested. The results of phenotypic testing can result in ambiguous OPT susceptibility and bile solubility (BS) test results (18).
Although they are uncommon, OPT resistance has been reported in S. pneumoniae and OPT-resistant subpopulations have also been reported, both of which may lead to problems in identification, especially in association with atypical colony morphologies (4, 13, 36, 42, 45, 46, 55, 60). Gardam and Miller (21) reported that variances in OPT zone sizes are dependent on the test medium and incubation environment used, as some media and environments may result in falsely reduced zone sizes.
Current recommendations for the identification of S. pneumoniae suggest incubation in 5% CO2 for OPT testing, based on reports that up to 8% of pneumococci will not grow aerobically, and that isolates showing zone sizes indicating susceptibility under aerobic incubation conditions are also susceptible when they are incubated in the presence of CO2 (API 20 Strep identification system for streptococci kit insert, 2003; bioMérieux, Inc., Durham, N.C.). Standardization of OPT susceptibility testing is further confused by the instructions of the Taxo disk manufacturer (BBL, Becton Dickinson Microbiology Systems, Cockeysville, Md.), which suggest that incubation in CO2 will enhance growth but reduce zone sizes (BBL Discs for Differentiation of Pneumococci kit insert, 1999; Becton Dickinson Microbiology Systems). The instructions are based on opposing recommendations published in the Manual of Clinical Microbiology (49) and a study published in 1971 by Ragsdale and Sanford (48). Ragsdale and Sanford recommended incubation in ambient air, on the basis of the reduced zone sizes obtained when tests were incubated in CO2, whereas the Manual of Clinical Microbiology recommends incubation in CO2 to enhance the growth of isolates that will not grow aerobically.
Bile-insoluble strains of S. pneumoniae have also been reported (39, 43, 44), as have atypical OPT-resistant, BS-negative strains of S. pneumoniae (15, 19, 26, 31, 41, 43, 66).
A review of the literature indicates various methodologies for BS testing (3, 26, 34, 49). BS testing can be performed either with a broth culture of an organism or with colonies growing on a solid medium. Despite methodological variances, BS testing is associated with a sensitivity exceeding 98% and a specificity of 100% (7).
The API 20 Strep system (bioMerieux, Marcy l'Etoile, France) and various commercial biochemical-based tests have been evaluated for their abilities to differentiate viridans group streptococci (20, 24, 28, 32, 33). Generally, these tests do not differentiate S. pneumoniae from the Smit group without the addition of OPT and/or BS testing. In well-validated studies, Kikuchi and colleagues (33) and Kawamura (28) reported on a poor correlation between the results obtained with the API 20 Strep and the Rapid ID 32 Strep systems and those obtained by DNA-DNA hybridization within the Smit group by use of the Rapid ID32 Strep kit (28, 33).
A number of commercial rapid test kits are available. These rely on visible detection of an antigen-antibody complex resulting from the reaction between pneumococcal surface antigens and type-specific antibodies (Directigen S. pneumoniae test kit insert, 1994 [Becton Dickinson Microbiology Systems, Cockeysville, Md.]; Phadebact Pneumococcus test insert, 2002 [Boule Diagnostics AB, Huddinge, Sweden]; Pneumoslide capsular agglutination test kit insert, 2002 [Becton Dickinson]; Slidex Pneumo-kit insert, 2001 [bioMerieux Canada, Inc., Quebec, Quebec, Canada]). All of these tests are based on the use of Statens Serum Institute Omni serum, a reagent that contains capsular antibodies to all known serotypes of S. pneumoniae. Conflicting reports of sensitivity and specificity exist (6, 7, 8, 12, 35, 37, 40, 53, 56, 63). One of the limitations of the agglutination test kits, as with other immunologic techniques, is that pneumococcal cells without capsules may not react, resulting in false-negative results. In addition, antisera may cross-react with some nonpneumococcal viridans group streptococci, resulting in false-positive results (8, 35, 53, 56, 63).
Molecular techniques such as PCR tests for the virulence genes of S. pneumoniae (autolysin [lytA] and pneumolysin [ply]) (9, 10, 15, 23, 26, 29, 30, 31, 39, 40, 50, 52, 59, 61, 62, 65, 66, 67) and penicillin binding protein genes are beginning to gain popularity, as are probe hybridization tests for specific regions of the 16S rRNA gene (16S rDNA) (8, 11, 13, 19, 31, 39, 41, 53, 64, 65).
While some investigators have concluded that amplification of a region of the lytA gene can be successfully used to identify S. pneumoniae (15, 23, 40, 50), others have demonstrated the presence of lytA in members of the Smit group (29, 47, 66) Although it is expected that all virulent isolates of S. pneumoniae possess the lytA gene, it cannot be presumed that isolates of all other members of the Smit group do not possess the lytA gene or may have a facsimile of a lytA gene. Therefore, the detection of lytA should be used cautiously to identify S. pneumoniae.
Detection of the ply gene and/or the expression of the Ply protein has also been used in direct detection assays with clinical samples and to differentiate S. pneumoniae from other viridans group streptococci, with various rates of success (9, 10, 26, 30, 31, 50, 52, 59, 62, 65, 66, 67). Although DNA amplification methods targeting the ply gene initially showed promise as a reliable, efficient method for confirmation of pneumococcal isolates, Kawamura and colleagues (29) and Whatmore and colleagues (66) have reported on the presence of the ply gene in strains of S. mitis and S. oralis, contraindicating its use in differentiating S. pneumoniae from other strains of the Smit group (30, 66). Similarly, although latex agglutination methods targeting the protein coded for by the ply gene showed promise (9, 31), their use, too, is contraindicated by the finding of the ply gene in members of the Smit group other than S. pneumoniae.
16S rRNA gene sequencing has limited use for the identification of S. pneumoniae because of the genetic similarity between species of the Smit group (22, 27, 29, 43). Whereas DNA-DNA homology studies show 40 to 60% similarity between members of the Smit group, the sequence similarity of the 16S rRNA genes of the type strains of S. mitis, S. oralis, and S. pneumoniae is reportedly greater than 99% (27, 29). Despite these reports of high similarity values for the 16S rRNA gene among members of the Smit group, a DNA probe hybridization test targeting a section of the rRNA specific to S. pneumoniae has been developed and is commercially available (AccuProbe Streptococcus pneumoniae culture identification test [GP]; Gen-Probe, San Diego, Calif.). Evaluation of the DNA probe hybridization test has resulted in conflicting reports in accuracy (11, 13, 19, 31, 41, 53, 64, 65). Mundy and colleagues (41), Kaijalainen and colleagues (26), and Whatmore and colleagues (66) reported controversial GP results in a study with atypical pneumococci; however, the strains used to evaluate the test were not definitively identified as S. pneumoniae (26, 41, 66) A number of studies have used GP to confirm the identities of isolates with discordant results obtained by other methodologies (8, 19, 31, 33, 64). However, there are no published results to support the use of GP as a "gold standard."
Studies with housekeeping genes (i.e., xpt, recP, HexB, and ddl) and the manganese-dependent superoxide dismutase gene (sodA) have shown promise for the use of these genes to differentiate strains of S. pneumoniae from other strains of the Smit group (29, 39, 43, 47, 66).
DNA-DNA reassociation is the gold standard for the identification of strains to the species level and is reportedly the most accurate means of identifying species within the Smit group (28, 29). However, testing of this type is not feasible for most clinical laboratories. Species identification is based on DNA hybridization with the DNA of type strains of greater than 70%. DNA-DNA similarity values based on the entire genome are estimated to be less than 60% for S. mitis, S. oralis, and S. pneumoniae (28).
During the course of study with S. pneumoniae clinical isolates we detected a distinct streptococcus. Here we report on the isolation and identification of a streptococcus phenotypically and genetically distinct from S. pneumoniae and the other members of the viridans group streptococci, including the Smit group. We propose a species designation for this organism, for which the name Streptococcus pseudopneumoniae is suggested.
|
|
|---|
Eighty-seven previously identified BS-positive S. pneumoniae isolates were selected from consecutive lower respiratory tract, eye, blood, and cerebrospinal fluid samples and tested by GP and the Phadebact Pneumococcus test, in addition to testing for OPT susceptibility in CO2 and O2, to determine the sensitivities of the GP and Phadebact Pneumococcus test methods. A PCR for the presence of the lytA and ply genes was also performed. Additionally, 35 previously identified viridans group streptococcus species were randomly selected to determine the specificities of the OPT test, BS test, Phadebact Pneumococcus test, GP, and PCR for the presence of the lytA and ply genes.
A positive control (S. pneumoniae ATCC 33400T) and a negative control (S. mitis ATCC 49456T) were included in all assays. The type strains of all members of the S. mitis group described by Facklam were also included in the study for comparison purposes (18).
OPT test. Repeat OPT susceptibility testing was performed in O2 and 5% CO2 environments for isolates rejected from the national susceptibility surveillance program. SBA plates were inoculated with colonies from overnight cultures with a loop, the OPT disk was placed in the center of the inoculum, and then the plate was incubated for 18 to 24 h at 35°C in both atmospheres.
BS test. The tube BS test was performed as described in the Clinical Microbiology Procedures Handbook (25). Suspensions were prepared in 1 ml of 0.85% NaCl, equivalent to a McFarland 1.0 standard.
GP. GP, based on the rRNA gene sequence, was performed according to the instructions of the manufacturer.
Coagglutination test. Subcultures of isolates were tested for coagglutination by the Phadebact Pneumococcus Test (Boule Diagnostics AB) according to the instructions of the manufacturer.
API 20 Strep system for identification of streptococci. The inoculation, incubation, and reading of the test results were carried out according to the instructions of the manufacturer.
DNA extraction. Template DNA was prepared by suspending a loopful of bacteria, grown overnight on SBA in 200 µl of 0.1 M Tris (pH 7.4). Five microliters of 100 µg of proteinase K per ml in sterile distilled water was added to the suspension, and the mixture was incubated at 37°C for 15 min and then boiled for 10 min. Once the mixture was cooled, samples were centrifuged and 2.5 µl of the supernatant was used as the template in the PCR.
Pneumolysin gene (ply) and autolysin gene (lytA) PCR. The presence of the ply and lytA genes in the extracted DNA was determined by PCR with primers specific for a 170-bp region of the ply gene and for a 273-bp region of the lytA gene, as described previously (61, 67). The PCR products were resolved by electrophoresis on 1.5% agarose gels to which ethidium bromide was added.
sodA gene PCR and sequencing. Forty-one isolates, including the 35 atypical strains, were submitted blindly to the Laboratoire Mixte Pasteur-Necker de Recherche sur les Streptococques et Streptoccies, Faculté de Médecine Necker-Enfants Malades, Paris, France, for sodA gene PCR and sequence analysis. Sequencing was carried out as described previously (47).
16S rRNA gene sequence and phylogenetic analysis. DNA extraction and purification were done with a QIAamp DNA Mini kit (Qiagen Inc., Valencia, Calif.), according to the instructions of the manufacturer. Purified genomic DNA was amplified by using the Expand High Fidelity PCR system (Roche, Indianapolis, Ind.) with primers fL1 and rL1 (54). The amplification conditions were 94°C for 5 min; 35 cycles of 94°C for 15 s, 50°C for 15 s, and 72°C for 90 s; and a final single extension of 72°C for 5 min, followed by a hold at 4°C. The products were confirmed by running 10 µl on a 1.0% (wt/vol) agarose gel for 30 min at 75 V. Excess deoxynucleoside triphosphates and primers were inactivated by the ExoSAP-IT method (U.S. Biochemical Corp., Cleveland, Ohio). Cycle sequencing was performed by use of Big Dye (version 3.1) dye terminator chemistry (Applied Biosystems, Foster City, Calif.) by the protocols suggested by Sacchi et al. (51). Excess dyes were removed with magnetic carboxylate beads (Agencourt Bioscience, Beverly, Mass.), and the reaction products were sequenced on an ABI 3100 sequencer (Applied Biosystems). Sequences were assembled by use of the Genetics Computer Group's Seqmerge program (Wisconsin software package, version 10.2) and trimmed to at least two confirming readings. Pairwise comparisons of novel sequences with the sequences in GenBank were performed with the BLAST program. Related entries were aligned in the Pileup program (14) and trimmed to a consensus sequence, and further analysis was performed with Bioedit and Treecon software. With the Bioedit software, the sequences were realigned by use of the Clustal W program (58) with 1,000 bootstraps, and a distance matrix was created. The distances of the aligned sequences were estimated by the Jukes-Cantor method in Treecon software with 1,000 bootstraps, and tree topology was determined by the neighbor-joining method. The final phylogenetic tree was rooted with an outgroup, and bootstrap values above 85% were displayed as percentages.
DNA-DNA reassociation. DNA-DNA reassociation studies were performed with five strains (strains 0207, 0225, 0102, 0103, and 0108) from the BS-negative, OPT-variable, and GP-positive group of isolates. Harvesting and lysis of the bacterial cells were performed as described previously (57). Extraction and purification of DNA and determination of DNA relatedness by the hydroxyapatite hybridization method were performed as described by Brenner and colleagues (5). DNA hybridization experiments were performed at 55°C for optimal DNA reassociation and at the stringent DNA reassociation temperature of 70°C. The levels of divergence within related sequences were determined by assuming that each degree of heteroduplex instability was caused by approximately 1% unpaired bases. Divergence, expressed by the change in melting temperature, is the decrease in the thermal stability (in degrees Celsius) of the heterologous DNA duplex relative to that of the homologous duplexes. Divergence was calculated to the nearest 0.5%. The G+C content was determined by the optical melting temperature and equilibrium buoyant methods by the procedures of Mandel and colleagues (38). All samples were run at least three times, with DNA from Escherichia coli K-12 used as a control.
Nucleotide sequence accession numbers. The sequences of strains S. pseudopneumoniae ATCC BAA-960T (CCUG 49455T) and ATCC BAA-891 (CCUG 48465) and S. pneumoniae ATCC 33400T have been deposited in GenBank under accession numbers AY612844, AY485599, and AY485600, respectively.
|
|
|---|
14 mm. Subsequently, 46 (21%) of the isolates identified as S. pneumoniae were rejected by the surveillance program on the basis of OPT resistance (zone size, <14 mm) when they were incubated in CO2 and negative BS test results. Upon retesting of these 46 isolates, 8 strains were found to be OPT and BS positive and were serotyped at the Centers for Disease Control and Prevention (CDC); 2 strains were OPT, BS, and GP negative and were presumed to be viridans group streptococci. One strain was omitted because we could not repeat the original reactions. The remaining 35 strains are the subject of the remainder of this study and are called OPT-variant (OPT-V) strains.
Of the 87 previously identified BS-positive pneumococcal isolates that were selected from consecutive lower respiratory tract, eye, blood, and cerebrospinal fluid samples for further testing, only one produced an zone of inhibition of <14 mm with an OPT disk in an atmosphere of increased CO2; and all isolates demonstrated zones of inhibition
14 mm with OPT disks when the test was incubated in ambient air. All strains were positive by the tube BS test, including the one strain with an inhibition zone <14 mm with the OPT disk. All of the typical S. pneumoniae strains were Phadebact test and GP positive. All 87 previously identified S. pneumoniae strains demonstrated amplification products of the appropriate sizes for the ply and lytA genes (Table 1).
|
View this table: [in a new window] |
TABLE 1. Phenotypic and genotypic test results for typical BS S. pneumoniae, OPT-V strains, and viridans group streptococci
|
|
View this table: [in a new window] |
TABLE 2. Phenotypic and genotypic test results for OPT-V strains of streptococcia
|
None of the 35 OPT-V strains were positive by the tube BS test. All 35 OPT-V isolates agglutinated in the Phadebact Pneumococcus test (Table 1). Twenty-seven of the 33 strains tested by GP were positive, resulting in the identification of S. pneumoniae. With the exception of strain 0211, which tested positive by GP at CDC, the remaining five OPT-V, BS-, and GP-negative strains (strains 0107, 0203, 0206, 0209, and 0218) were not investigated further.
Twenty-four of the 35 OPT-V strains demonstrated a truncated amplification product of approximately 200 bp by PCR with primers targeting a 273-bp region of the lytA gene. Eleven isolates failed to produce a product by PCR with the lytA gene primers (Tables 1 and 2). All 35 of the OPT-V isolates demonstrated the expected 170-bp ply gene amplification product (Tables 1 and 2).
Only 1 of the 35 viridans group streptococci had a zone of inhibition >14 mm in tests with OPT disks when the strains were incubated in an atmosphere with increased levels of CO2. However, when the strains were incubated in ambient air, three viridans group streptococcal strains had inhibition zones >14 mm. The strains with small zones of inhibition and with zone sizes
14 mm were all identified as S. mitis. None of the 35 strains of viridans group streptococci were tube BS test positive. Ten of the 35 viridans group streptococci tested coagglutinated by the Phadebact test; 9 of these were previously identified as S. mitis, while 1 was identified as S. oralis and 1 was identified as S. salivarius (Table 1). Two of these strains demonstrated an amplification product of the appropriate size for the ply gene, and one demonstrated a truncated lytA gene product (Tables 1 and 2). Four of the 35 viridans group streptococci, all identified as S. mitis, tested positive by the PCR for ply.
Comparison of OPT, BS, and GP (QEII and CDC).
The results obtained by the OPT disk test with incubation under an atmosphere with increased CO2 or in ambient air are listed in Table 2. The inhibition zones seen with incubation in ambient air were much larger than those seen with incubation in an atmosphere of increased CO2. When the OPT disk test was incubated under an atmosphere with increased CO2 levels, no zones of inhibition were observed with 18 of the 35 strains in either laboratory. Nine additional strains had no inhibition zones when they were tested in the CDC laboratory, but they had small inhibition zones (9 to 11 mm) when they were tested in the QEII laboratory. Four strains had larger inhibition zones in the QEII laboratory, while three others had larger inhibition zones in the CDC laboratory. Only two strains in each laboratory had inhibition zones >14 mm and would have been erroneously identified as S. pneumoniae if no other test had been used for identification. When the OPT disk test was incubated in an ambient air atmosphere, 29 strains in each laboratory showed inhibition zones
14 mm. Only two strains showed zones of inhibition less than 14 mm in both laboratories. There was no pattern of increased inhibition zone sizes in one laboratory versus the other; inhibition zones were larger in the QEII laboratory for 14 strains, and inhibition zones were larger in the CDC laboratory for 18 strains; inhibition zone sizes were identical for 3 strains at both laboratories. The tube BS test was used in both the CDC and the QEII laboratories. None of the 35 OPT-V strains were positive in either laboratory (Table 2). The GP results were positive and correlated for 27 of the 28 strains tested in both laboratories. One strain, 0211 (Table 2), was positive at the CDC laboratory but negative at the QEII laboratory.
Serotyping. All 35 OPT-V strains listed in Table 1 failed to react with CDC pneumococcal typing antiserum. All 11 strains of S. pneumoniae tested were positive by tests with the CDC Quellung typing antisera: 3 strains were type 6B; 2 strains were type 14; 2 strains were type 31; and 1 strain each was type 7F, 11A, 16F, and 18C. Four viridans group streptococci did not react with any of the pooled antisera from CDC.
Evaluation of the API 20 Strep identification system for streptococci. Biochemical testing was done with 13 isolates; 10 OPT-V strains (1 in duplicate), 1 OPT-V but GP-negative strain, and 1 S. pneumoniae reference strain. This system failed to definitively identify any of the isolates to the species level (Table 3). In all cases, additional testing was suggested; often, additional testing involved OPT susceptibility testing and/or solubility in bile, two tests that in most cases would have been performed prior to use of the API test strip. Two identical API profiles (0060000 and 0060400) were observed for four strains each, and three other strains had unique profiles. In some cases the additional tests did not result in a definitive identification, which was the correct identification, since four of these strains (strains 0102, 0103, 0108, and 0207) have been shown to be a new species of the viridans group streptococci.
|
View this table: [in a new window] |
TABLE 3. Biochemical test results (API 20 Strep system) for subset of strains
|
![]() View larger version (11K): [in a new window] |
FIG. 1. Phylogenetic tree, based on comparative analysis of the sodA gene sequences, showing the relationship of S. pseudopneumoniae sp. nov. and related species of the genus Streptococcus.
|
![]() View larger version (17K): [in a new window] |
FIG. 2. Phylogenetic tree, based on comparative analysis of the 16S rDNA sequences, showing the relationship of S. pseudopneumoniae sp. nov. and related species of the Smit group. The limit criterion used to show the bootstrap numbers was above 85%, and S. pyogenes was used as the outgroup.
|
|
View this table: [in a new window] |
TABLE 4. DNA-DNA hybridization reactions of OPT-V, bile-insoluble, and GP-positive strainsa
|
|
|
|---|
OPT susceptibility testing is the test most commonly used in clinical microbiology laboratories to screen alpha-hemolytic colonies for the identification of pneumococci; however, it remains unclear whether incubation in CO2, as recommended in the Manual of Clinical Microbiology (49), or ambient atmosphere, as recommended by the manufacturer of Taxo OPT test disks, is optimal for the identification of pneumococci. The data collected in this study suggest that while incubation in CO2 on SBA is more specific, it is less sensitive than BS testing. Three of 87 BS-positive S. pneumoniae isolates would have been missed by OPT susceptibility testing in CO2 alone (3.4%). Two of these strains had no zone at all when they were incubated in CO2 but had zones of 18 and 22 mm, respectively, when they were incubated in O2. The other strain, which had a small inhibition zone of 12 mm, would have been tested for BS, and a correct identification would have resulted. Although OPT susceptibility testing in O2 alone selected these isolates, it also selected five isolates (14%) previously identified as S. mitis. Approximately 18% of the isolates from lower respiratory tract samples, identified as S. pneumoniae by OPT susceptibility testing in O2, fit into this variant group of viridans group streptococci. Further studies are needed to determine whether this new species of viridans group streptococci, S. pseudopneumoniae, has pathogenic potential. Until the pathogenicity of S. pseudopneumoniae is determined, our recommendation for OPT susceptibility testing on SBA is incubation in CO2, unless BS testing is also performed simultaneously. If S. pseudopneumoniae is subsequently found to be pathogenic, OPT susceptibility testing of BS-negative, GP-positive isolates in both CO2 and O2 environments may be useful for the differentiation of S. pneumoniae from S. pseudopneumoniae.
During the course of the study, we observed variations in the results of BS tests performed with the same isolates by technologists at three different institutions using different methodologies. Microbiology texts are not consistent on the method that should be used to test for BS. The Manual of Clinical Microbiology (49) suggests one method in the chapter on streptococci, but it refers to a different method in the section on reagents, stains, and media. The method described in the Manual of Clinical Microbiology appears to be more consistent in identifying strains with weak expressions of solubility in bile (data not shown).
Identification of autolysin and/or pneumolysin virulence genes initially showed promise for use in the identification of pneumococci (9, 10, 15, 23, 26, 29, 30, 31, 39, 40, 50, 52, 59, 61, 62, 65, 66, 67). However, although these genes are present in all pneumococcal strains, a number of investigators have also reported their presence in viridans group streptococci other than S. pneumoniae (28, 29, 47, 66). In this study, we were able to demonstrate PCR products of the expected size for the pneumolysin virulence gene (ply) in 4 of the 16 S. mitis strains tested and in all 35 of the OPT-V strains subsequently identified as S. pseudopneumoniae. An amplification product of the expected size for the lytA gene (
273 bp) was also found for 1 of the 16 S. mitis strains, and a truncated product of approximately 200 bp was demonstrated for 2 of the 16 S. mitis strains and 22 of the OPT-V strains subsequently identified as S. pseudopneumoniae. It is unclear whether the S. pseudopneumoniae strains that tested negative for the autolysin gene are truly negative or whether they harbor remnants of the autolysin gene that were not amplified by our primers. Sequencing of the regions upstream and downstream of the autolysin gene is necessary to determine this.
Not surprisingly, the API 20 Strep system (bioMerieux) showed poor specificity with the isolates tested, and in all cases, additional testing was required before an identification could be made. Although only a small number of isolates tested were in this study, the results are consistent with those published previously (20, 28, 33). Kikuchi and colleagues (33) and Kawamura (28) reported a poor correlation between the results obtained with the API 20 Strep and Rapid ID 32 Strep systems and those obtained by DNA-DNA hybridization within the Smit group by use of the Rapid ID32 Strep kit (28, 33). Fordymacki and colleagues (20) also reported a poor correlation of the results obtained by using the API 20 Strep, Rapid ID 32 Strep (bioMerieux), and Streptoplast PPL 18 (HTL, Warsaw, Poland) systems with S. pneumoniae and recommended that these systems not be used for the identification of pneumococci.
Although the sensitivity of the Phadebact Pneumococcus coagglutination kit was excellent (87 of 87 S. pneumoniae isolates were correctly identified), its specificity was extremely poor. All 35 of the variant isolates, subsequently identified as a new species of streptococci, S. pseudopneumoniae, were positive; and 10 of the 35 viridans group streptococci tested also gave positive results: 8 of 16 strains were S. mitis, 1 of 6 strains was S. oralis, and 1 of 6 strains was S. salivarius. On the basis of these results, the Phadebact Pneumococcus coagglutination kit is not recommended for use for the identification of S. pneumoniae in the absence of a confirmatory test, such as the BS test.
16S rRNA gene sequencing showed a very close relationship between S. pneumoniae and S. pseudopneumonaie. Emler and colleagues (S. Emler, N. Liassine, J. Pawlowsky, B. Hirschel, P. Rohner, and R. Auckenthaler, Abstr. 97th Gen. Meet. Am. Soc. Microbiol., poster D-155, 1997) demonstrated a high degree of homology and minor differences in distinct positions that allowed differentiation of closely related species, such as S. mitis and S. pneumoniae. However, other investigators have found that although sequencing of 16S rDNA is an excellent tool for the identification of most organisms, it does not have sufficient discriminatory power to differentiate members of the mitis group of streptococci (22, 27, 29, 43).
The GP investigators have chosen a sequence of the rRNA gene for their test that does not discriminate between S. pneumoniae and S. pseudopneumoniae. Our results indicate that the portion of the sequence may be identical for both species. OPT-resistant, BS-negative, and GP-positive isolates have been observed in other laboratories; however, DNA homology studies were not performed to definitively identify these isolates (15, 19, 26, 31, 41, 43, 66; W. H. Haas [University of Washington], personal communication, 2003). It seems likely, on the basis of test characteristics, that these isolates may, in fact, be S. pseudopneumoniae and not S. pneumoniae, as reported. Further studies with definitive identification methods, such as DNA homology analysis, and an assortment of BS-negative, OPT-resistant, and OPT-V strains are required to determine the specificity of GP. Although it is possible that the manufacturer has targeted a region of the 16S rRNA gene that distinguishes S. pneumoniae from other viridans group streptococci, preliminary results from this study suggest that GP lacks the discriminatory power necessary to separate S. pneumoniae from S. pseudopneumoniae.
Sequencing of an internal segment of the sodA gene also showed promise for the identification of S. pneumoniae; however, the results obtained in this study indicate that sequencing of the region targeted by our primers lacks the discriminatory power to differentiate S. pseudopneumoniae from S. pneumoniae. This may indicate that the new species, S. pseudopneumoniae, has a sodA gene identical to that of S. pneumoniae.
Difficulties with the identification of S. pneumoniae and other naturally competent organisms may be caused by horizontal transfer of heterologous genes and evolution, resulting in an evolutionary soup. Taxonomists have a tendency to create static divisions of microorganisms, but in reality, nature contains many mosaic organisms that do not clearly fit into any particular species over time.
The accurate identification of viridans group streptococci, including S. pneumoniae, remains problematic. Until such time as the pathogenicity of S. pseudopneumoniae is determined, pneumococcal identification protocols must include tests that can differentiate this new species from its closely related, clinically significant neighbor, S. pneumoniae. Observations made during the course of this study suggest that BS testing is the most accurate of the phenotypic tests used in the clinical laboratory for the identification of pneumococci, although problems may be encountered when one is dealing with weakly bile-soluble strains. OPT susceptibility testing remains a useful screening test; however, the manufacturer's recommendation for incubation in an ambient environment should be changed to a recommendation for incubation in CO2 to exclude selection of S. pseudopneumoniae.
Sequencing of the autolysin genes of S. pneumoniae and S. pseudopneumoniae may provide regions that are useful for the development of a probe that will differentiate S. pneumoniae from S. pseudopneumoniae yet that will be feasible for routine use in the clinical laboratory, as GP is. Further investigation is required.
DNA homology testing of isolates previously described in the literature as atypical pneumococci is of particular interest to us and may provide evidence that isolates are more closely related to S. pseudopneumoniae than to S. pneumoniae or another member of the Smit group.
Further studies are required to determine the pathogenic potential of S. pseudopneumoniae. The identification of 35 of 195 isolates (18%) from lower respiratory tract specimens in this study would seem to indicate that it may have pathogenic potential, but without additional information this potential cannot be validated at this time.
There was a subgroup of strains other than S. pseudopneumoniae or S. pneumoniae that likely represent viridans group streptococci. These isolates exhibited the same OPT susceptibility variabilities demonstrated by S. pseudopneumoniae, but they were GP negative. DNA-DNA homology studies were not performed with these isolates.
Conclusions. DNA-DNA homology studies suggest that a subset of our isolates represent a novel species of the Smit group that is distinct from S. pneumoniae and S. mitis.
Performance of OPT susceptibility testing in a 5% CO2 environment is necessary to reduce the possibility of misidentification of S. pneumoniae. Solubility in bile appears to be the most reliable phenotypic test for the differentiation of S. pneumoniae from other species in the Smit group, including a novel species, designated S. pseudopneumoniae. S. pseudopneumoniae can be differentiated from S. pneumoniae and S. mitis by the demonstration of insolubility in bile, a zone size for resistance or indeterminate susceptibility (<14 mm with a 6-mm OPT disk) when it is incubated in CO2 and a zone size for susceptibility (
14 mm with a 6-mm OPT disk) following incubation in an ambient environment, and a positive reaction by GP. Standardization of OPT susceptibility testing and BS testing is required for consistent, reproducible results.
S. pseudopneumoniae strains react positively by genetic probe tests for the pneumolysin gene (ply), the manganese-dependent superoxide dismutase gene (sodA), and the rRNA gene by a commercial assay, GP. It is also probable that this species has a modified autolytic gene (lytA).
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»